Journal article

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.

  • Kuendgen A Department of Hematology, Oncology, and Clinical Immunology, University Hospital Duesseldorf, Duesseldorf, Germany. kuendgen@med.uni-duesseldorf.de.
  • Nomdedeu M Department of Laboratory Hematology, Institut Català d'Oncologia Hospital GermansTrias I Pujol, Badalona, Spain.
  • Tuechler H Boltzmann Institute for Leukemia Research, Hanusch Hospital, Vienna, Austria.
  • Garcia-Manero G Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
  • Komrokji RS Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Sekeres MA Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Della Porta MG Cancer Center - IRCCS Humanitas Research Hospital & Humanitas University, Rozzano - Milan, Italy.
  • Cazzola M Department of Hematology Oncology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  • DeZern AE Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
  • Roboz GJ Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY, USA.
  • Steensma DP Dana-Farber Cancer Institute, Boston, MA, USA.
  • Van de Loosdrecht AA Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
  • Schlenk RF Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
  • Grau J Department of Laboratory Hematology, Institut Català d'Oncologia Hospital GermansTrias I Pujol, Badalona, Spain.
  • Calvo X Hematological Citology Laboratory, Pathology Department, Hospital del Mar, GRETNHE, IMIM Hospital del Mar Research Institute, Barcelona, Spain.
  • Blum S Service of Hematology, University Hospital Lausanne, Lausanne, Switzerland.
  • Pereira A Hemotherapy and Hemostasis Department, Hospital Clínic de Barcelona IDIBAPS, Barcelona, Spain.
  • Valent P Department of Internal Medicine I, Division of Hematology & Hemostaseology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
  • Costa D Hematopathology Section, Hospital Clínic de Barcelona IDIBAPS, Barcelona, Spain.
  • Giagounidis A Department of Oncology, Hematology and Palliative Care, Marienhospital Duesseldorf, Duesseldorf, Germany.
  • Xicoy B Clinical Hematology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Döhner H Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
  • Platzbecker U University Hospital Leipzig, Leipzig, Germany.
  • Pedro C Clinical Hematology Department, Hospital del Mar, Barcelona, Spain.
  • Lübbert M Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, Freiburg, Germany.
  • Oiartzabal I Clinical Hematology Department, Hospital Universitario Araba, Vitoria-Gasteiz, Spain.
  • Díez-Campelo M Clinical Hematology Department, Hospital Universitario de Salamanca (HUSA), Salamanca, Spain.
  • Cedena MT Clinical Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Machherndl-Spandl S 1st. Internal Department - Hematology with stem cell transplants, Hemostaseology and Medical Oncology, Elisabethinen Hospital, Linz, Austria.
  • López-Pavía M Clinical Hematology Department, Hospital General Universitari de València, Valencia, Spain.
  • Baldus CD Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Martinez-de-Sola M Clinical Hematology Department, Hospital Parc Taulí, Sabadell, Spain.
  • Stauder R Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria.
  • Merchan B Department of Hematology, University Hospital Vall d´Hebrón, Barcelona, Spain.
  • List A Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Ganster C Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
  • Schroeder T Department of Hematology, Oncology, and Clinical Immunology, University Hospital Duesseldorf, Duesseldorf, Germany.
  • Voso MT Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.
  • Pfeilstöcker M Hanusch Krankenhaus Wien, Vienna, Austria.
  • Sill H Medizinische Universität Graz, Graz, Austria.
  • Hildebrandt B Institute of Human Genetics, University Duesseldorf, Duesseldorf, Germany.
  • Esteve J Clinical Hematology Department, Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain.
  • Nomdedeu B Clinical Hematology Department, Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain.
  • Cobo F Clinical Hematology Department, Hospital Quirón Teknon, Barcelona, Spain.
  • Haas R Department of Hematology, Oncology, and Clinical Immunology, University Hospital Duesseldorf, Duesseldorf, Germany.
  • Sole F MDS Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.
  • Germing U Department of Hematology, Oncology, and Clinical Immunology, University Hospital Duesseldorf, Duesseldorf, Germany.
  • Greenberg PL Stanford University Cancer Center, Stanford, CA, USA.
  • Haase D Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
  • Sanz G Clinical Hematology Department, Hospital Universitari I Politècnic la Fe, Valencia, Spain.
Show more…
  • 2020-06-30
Published in:
  • Leukemia. - 2020
English In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic/myeloproliferative neoplasms into one subgroup independent of morphologic or prognostic features. Analyzing data of 2087 t-MDS patients from different international MDS groups to evaluate classification and prognostication tools we found that applying the WHO classification for p-MDS successfully predicts time to transformation and survival (both p < 0.001). The results regarding carefully reviewed cytogenetic data, classifications, and prognostic scores confirmed that t-MDS are similarly heterogeneous as p-MDS and therefore deserve the same careful differentiation regarding risk. As reference, these results were compared with 4593 primary MDS (p-MDS) patients represented in the International Working Group for Prognosis in MDS database (IWG-PM). Although a less favorable clinical outcome occurred in each t-MDS subset compared with p-MDS subgroups, FAB and WHO-classification, IPSS-R, and WPSS-R separated t-MDS patients into differing risk groups effectively, indicating that all established risk factors for p-MDS maintained relevance in t-MDS, with cytogenetic features having enhanced predictive power. These data strongly argue to classify t-MDS as a separate entity distinct from other WHO-classified t-myeloid neoplasms, which would enhance treatment decisions and facilitate the inclusion of t-MDS patients into clinical studies.
Language
  • English
Open access status
hybrid
Identifiers
Persistent URL
https://sonar.ch/global/documents/740
Statistics

Document views: 55 File downloads:
  • Full-text: 0